WO2001072280A3 - Microspheres for gene therapy - Google Patents
Microspheres for gene therapy Download PDFInfo
- Publication number
- WO2001072280A3 WO2001072280A3 PCT/US2001/009618 US0109618W WO0172280A3 WO 2001072280 A3 WO2001072280 A3 WO 2001072280A3 US 0109618 W US0109618 W US 0109618W WO 0172280 A3 WO0172280 A3 WO 0172280A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gene therapy
- angiogenic
- microspheres
- injectable compositions
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/220,983 US20030212022A1 (en) | 2001-03-23 | 2001-03-23 | Compositions and methods for gene therapy |
AU2001245987A AU2001245987A1 (en) | 2000-03-24 | 2001-03-23 | Compositions and methods for gene therapy |
US11/253,435 US20060063732A1 (en) | 2000-03-24 | 2005-10-18 | Compositions and methods for gene therapy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19190200P | 2000-03-24 | 2000-03-24 | |
US60/191,902 | 2000-03-24 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/253,435 Continuation US20060063732A1 (en) | 2000-03-24 | 2005-10-18 | Compositions and methods for gene therapy |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001072280A2 WO2001072280A2 (en) | 2001-10-04 |
WO2001072280A3 true WO2001072280A3 (en) | 2002-01-31 |
Family
ID=22707377
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/009618 WO2001072280A2 (en) | 2000-03-24 | 2001-03-23 | Microspheres for gene therapy |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2001245987A1 (en) |
WO (1) | WO2001072280A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8951989B2 (en) | 2009-04-09 | 2015-02-10 | Actamax Surgical Materials, Llc | Hydrogel tissue adhesive having reduced degradation time |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7332160B2 (en) | 2002-07-12 | 2008-02-19 | Boston Scientific Scimed, Inc. | Medical device and method for tissue removal and repair |
US20060069168A1 (en) * | 2002-10-29 | 2006-03-30 | Norikazu Tabata | Vascular embolization material |
FR2858628B1 (en) * | 2003-08-04 | 2008-01-04 | Polyplus Transfection | NOVEL NUCLEIC ACID COMPLEXES FOR RNA INTERFERENCE AND THEIR USE FOR INHIBITING PROTEIN EXPRESSION |
US8821859B2 (en) * | 2004-05-19 | 2014-09-02 | Agency For Science, Technology And Research | Methods and articles for the delivery of therapeutic agents |
DE602005027862D1 (en) | 2004-10-07 | 2011-06-16 | Du Pont | POLYMER BASED ON POLYSACCHARIDE FOR TISSUE ADHESIVES FOR MEDICAL USE |
EP1844772A1 (en) * | 2006-04-06 | 2007-10-17 | Polyplus-Transfection SA | Compositions for transfection of oligonucleotides active for gene silencing and their biological and therapeutical applications |
US8282959B2 (en) | 2006-11-27 | 2012-10-09 | Actamax Surgical Materials, Llc | Branched end reactants and polymeric hydrogel tissue adhesives therefrom |
WO2009029443A2 (en) * | 2007-08-24 | 2009-03-05 | E. I. Du Pont De Nemours And Company | Method for embolization using liquid embolic materials |
EP2214731B1 (en) | 2007-11-14 | 2014-05-14 | Actamax Surgical Materials LLC | Oxidized cationic polysaccharide-based polymer tissue adhesive for medical use |
US8551136B2 (en) | 2008-07-17 | 2013-10-08 | Actamax Surgical Materials, Llc | High swell, long-lived hydrogel sealant |
WO2010017215A2 (en) * | 2008-08-04 | 2010-02-11 | The Regents Of The University Of California | Biodegradable microspheres and methods of use thereof |
US8466327B2 (en) | 2008-11-19 | 2013-06-18 | Actamax Surgical Materials, Llc | Aldehyde-functionalized polyethers and method of making same |
US9044529B2 (en) | 2008-11-19 | 2015-06-02 | Actamax Surgical Materials, Llc | Hydrogel tissue adhesive formed from aminated polysaccharide and aldehyde-functionalized multi-arm polyether |
WO2011002956A1 (en) | 2009-07-02 | 2011-01-06 | E. I. Du Pont De Nemours And Company | Aldehyde-functionalized polysaccharides |
US8580950B2 (en) | 2009-07-02 | 2013-11-12 | Actamax Surgical Materials, Llc | Aldehyde-functionalized polysaccharides |
US9758606B2 (en) | 2012-07-31 | 2017-09-12 | The Trustees Of Columbia University In The City Of New York | Cyclopropenium polymers and methods for making the same |
US8859705B2 (en) | 2012-11-19 | 2014-10-14 | Actamax Surgical Materials Llc | Hydrogel tissue adhesive having decreased gelation time and decreased degradation time |
EP3027659B1 (en) | 2013-07-29 | 2020-12-09 | Actamax Surgical Materials LLC | Low swell tissue adhesive and sealant formulations |
GB201315321D0 (en) | 2013-08-28 | 2013-10-09 | Koninklijke Nederlandse Akademie Van Wetenschappen | Transduction Buffer |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992021327A1 (en) * | 1991-05-29 | 1992-12-10 | Sepracor, Inc. | Microspheres useful for therapeutic vascular occlusions and injectable solutions containing the same |
WO1996011671A1 (en) * | 1994-10-12 | 1996-04-25 | Focal, Inc. | Targeted delivery via biodegradable polymers |
EP0797988A2 (en) * | 1993-07-19 | 1997-10-01 | Angiotech Pharmaceuticals, Inc. | Anti-angiogenic compositions and methods of use |
WO1999058694A1 (en) * | 1998-05-12 | 1999-11-18 | The Regents Of The University Of California | Methods of forming protein-linked lipidic microparticles, and compositions thereof |
-
2001
- 2001-03-23 WO PCT/US2001/009618 patent/WO2001072280A2/en active Application Filing
- 2001-03-23 AU AU2001245987A patent/AU2001245987A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992021327A1 (en) * | 1991-05-29 | 1992-12-10 | Sepracor, Inc. | Microspheres useful for therapeutic vascular occlusions and injectable solutions containing the same |
EP0797988A2 (en) * | 1993-07-19 | 1997-10-01 | Angiotech Pharmaceuticals, Inc. | Anti-angiogenic compositions and methods of use |
WO1996011671A1 (en) * | 1994-10-12 | 1996-04-25 | Focal, Inc. | Targeted delivery via biodegradable polymers |
WO1999058694A1 (en) * | 1998-05-12 | 1999-11-18 | The Regents Of The University Of California | Methods of forming protein-linked lipidic microparticles, and compositions thereof |
Non-Patent Citations (6)
Title |
---|
DASS C R (REPRINT) ET AL: "Microsphere -mediated targeted gene therapy of solid tumors", DRUG DELIVERY, (OCT-DEC 1999) VOL. 6, NO. 4, PP. 243-252. PUBLISHER: TAYLOR & FRANCIS INC, 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106. ISSN: 1071-7544., October 1999 (1999-10-01) - December 1999 (1999-12-01), HEART RES INST, CELL BIOL UNIT, 145 MISSENDEN RD, CAMPERDOWN, NSW 2050, AUSTRALIA (Reprint);CHARLES STURT UNIV, SCH BIOMED SCI, WAGGA WAGGA, NSW, AUSTRALIA, XP001030922 * |
DASS, CRISPIN R. ET AL: "A microsphere -lipoplex (microplex) vector for targeted gene therapy of cancer. I. Construction and in vitro evaluation", DRUG DELIVERY (1999), 6(4), 259-269, - 1999, XP001030923 * |
ESPOSITO E. ET AL: "Preparation and characterization of cationic microspheres for gene delivery.", INTERNATIONAL JOURNAL OF PHARMACEUTICS, (1999) 189/1 (29-41)., - 1999, XP001030974 * |
KALYANASUNDARAM S ET AL: "COACERVATE MICROSPHERES AS CARRIERS OF RECOMBINANT ADENOVIRUSES", CANCER GENE THERAPY, NORWALK, CT, US, vol. 6, no. 2, March 1999 (1999-03-01), pages 107 - 112, XP000904789, ISSN: 0929-1903 * |
LUO DAN ET AL: "Controlled DNA delivery systems.", PHARMACEUTICAL RESEARCH (NEW YORK), vol. 16, no. 8, August 1999 (1999-08-01), pages 1300 - 1308, XP001030924, ISSN: 0724-8741 * |
MATTHEWS C B ET AL: "POLY-L-LYSINE IMPROVES GENE TRANSFER WITH ADENOVIRUS FORMULATED IN PLGA MICROSPHERES", GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 6, no. 9, September 1999 (1999-09-01), pages 1558 - 1564, XP000971877, ISSN: 0969-7128 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8951989B2 (en) | 2009-04-09 | 2015-02-10 | Actamax Surgical Materials, Llc | Hydrogel tissue adhesive having reduced degradation time |
Also Published As
Publication number | Publication date |
---|---|
WO2001072280A2 (en) | 2001-10-04 |
AU2001245987A1 (en) | 2001-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001072281A3 (en) | Microspheres for active embolization | |
WO2001072280A3 (en) | Microspheres for gene therapy | |
WO1999053943A3 (en) | Therapeutic angiogenic factors and methods for their use | |
WO2003082188A3 (en) | Methods and drug delivery systems for the treatment of orofacial diseases | |
WO2005079387A3 (en) | Implantable drug delivery device including wire filaments | |
WO1996025947A3 (en) | Induction of e-selectin for targetting therapeutic agents | |
WO2002047731A3 (en) | Drug delivery compositions and coated medical devices | |
WO2006002366A3 (en) | Biodegradable ocular devices, methods and systems | |
WO1998029105A3 (en) | Method of treating prostatic diseases using delayed and/or sustained release vitamin d formulations | |
TW200950764A (en) | An intrauterine system | |
WO2002069848A3 (en) | Apparatus for stent deployment with delivery of bioactive agents | |
EP0737703A3 (en) | Hydrogel-forming , self-solvating absorbable polyester copolymers, and methods for use therefor | |
WO2005110436A3 (en) | Macromolecule-containing sustained release intraocular implants and related methods | |
WO2002045431A3 (en) | Genetically engineered herpes virus for the treatment of cardiovascular disease | |
WO2004041067A3 (en) | Prevention and treatment of synucleinopathic disease | |
CA2235919A1 (en) | Non-polymeric sustained release delivery system | |
NZ511984A (en) | Controlled release formulation comprising GnRH-II | |
MXPA03010085A (en) | Composition and methods for treatment of hyperplasia. | |
WO2006053159A3 (en) | Medical device for delivering biologically active material | |
WO2007112195B1 (en) | Intramedullary drug delivery device | |
MXPA02012666A (en) | Topical pharmaceutical formulations and methods of treatment. | |
WO2002004623A3 (en) | ANTISENSE COMPOSITIONS TARGETED TO β1 ADRENOCEPTOR-SPECIFIC MRNA AND METHODS OF USE | |
WO2003032815A3 (en) | Medical device for delivering patches | |
MXPA03004546A (en) | Treatment of mucositis. | |
EP1231864A4 (en) | Drug delivery catheters that attach to tissue and methods for their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10220983 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |